<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32043626</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1128</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Medicinal research reviews</Title><ISOAbbreviation>Med Res Rev</ISOAbbreviation></Journal><ArticleTitle>The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.</ArticleTitle><Pagination><StartPage>1352</StartPage><EndPage>1384</EndPage><MedlinePgn>1352-1384</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/med.21661</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by progressive loss of muscle function. It is the most common adult-onset form of motor neuron disease, affecting about 16&#x2009;000 people in the United States alone. The average survival is about 3 years. Only two interventional drugs, the antiglutamatergic small-molecule riluzole and the more recent antioxidant edaravone, have been approved for the treatment of ALS to date. Therapeutic strategies under investigation in clinical trials cover a range of different modalities and targets, and more than 70 different drugs have been tested in the clinic to date. Here, we summarize and classify interventional therapeutic strategies based on their molecular targets and phenotypic effects. We also discuss possible reasons for the failure of clinical trials in ALS and highlight emerging preclinical strategies that could provide a breakthrough in the battle against this relentless disease.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wobst</LastName><ForeName>Heike J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-9041-3241</Identifier><AffiliationInfo><Affiliation>Neuroscience, BioPharmaceuticals R&amp;D, AstraZeneca, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Korrie L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Dean G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Hit Discovery, Discovery Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandon</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-3917-0096</Identifier><AffiliationInfo><Affiliation>Neuroscience, BioPharmaceuticals R&amp;D, AstraZeneca, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5269-8533</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS090205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG061784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG065854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102687</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM099836</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Res Rev</MedlineTA><NlmUniqueID>8103150</NlmUniqueID><ISSNLinking>0198-6325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS preclinical strategies</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">edaravone</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList><CoiStatement>Conflict of interest. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32043626</ArticleId><ArticleId IdType="mid">NIHMS1554027</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="doi">10.1002/med.21661</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brennan F The 70th anniversary of the death of Lou Gehrig. Am J Hosp Palliat Care 29, 512&#x2013;514 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22363036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118&#x2013;130 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep 67, 1285&#x2013;1289 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH &amp; Al-Chalabi A Amyotrophic Lateral Sclerosis. N Engl J Med 377, 162&#x2013;172 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM &amp; Masson GL Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci 399, 217&#x2013;226 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Ciura S, Rouleau GA &amp; Kabashi E Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet 31, 263&#x2013;273 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25869998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M &amp; Cleveland DW Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L &amp; Shorter J Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. Cold Spring Harb Perspect Med 7(2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580514</ArticleId><ArticleId IdType="pubmed">27920024</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF &amp; Shorter J RNA-binding proteins with prion-like domains in health and disease. Biochem J 474, 1417&#x2013;1438 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaitakis A &amp; Caroscio JT Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22, 575&#x2013;579 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2892463</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaitakis A, Constantakakis E &amp; Smith J The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 24, 446&#x2013;449 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2906529</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6, 101&#x2013;104 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8664560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 3, 348&#x2013;359 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">9021256</ArticleId></ArticleIdList></Reference><Reference><Citation>Caramia MD, et al. &#x2018;Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroencephalogr Clin Neurophysiol 81, 243&#x2013;250 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1714817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 113, 1688&#x2013;1697 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12417221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L &amp; Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330, 585&#x2013;591 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P &amp; Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425&#x2013;1431 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD &amp; Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev, CD001447 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol 1, 996&#x2013;1005 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahao A, et al. First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun 10, 4373 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763482</ArticleId><ArticleId IdType="pubmed">31558719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham MC A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17, 4&#x2013;31 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13, 1083&#x2013;1091 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60, 22&#x2013;31 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzi P, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281&#x2013;285 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9440691</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11, 456&#x2013;460 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169, 13&#x2013;21 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi RM, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11, 266&#x2013;271 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, Teramoto S &amp; Kwak S The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6, 28649 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R ALSUntangled 48: Perampanel (Fycompa). Amyotroph Lateral Scler Frontotemporal Degener, 1&#x2013;4 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30786786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 7, 1&#x2013;11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology 86, 1474&#x2013;1481 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemporal Degener 16, 353&#x2013;358 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25960085</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29, 233&#x2013;249 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9551785</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56, 843&#x2013;848 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11294919</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 16, 505&#x2013;512 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, et al. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci 11, 11&#x2013;14 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai M, Ishizaki K, Matsuda H &amp; Sobue G Surveillance of using novel free radical scavenger, edaravone to investigate survival effect for ALS patients in Japan (SUNRISE Japan): A study design. Journal of the Neurological Sciences 381, 207 (2017).</Citation></Reference><Reference><Citation>Watanabe T, Yuki S, Egawa M &amp; Nishi H Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268, 1597&#x2013;1604 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8138971</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC &amp; Shaw PJ Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48, 629&#x2013;641 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213, 448&#x2013;455 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LM, Wang N, Lu Y &amp; Wang WP Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II. Brain Behav 9, e01156 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6346642</ArticleId><ArticleId IdType="pubmed">30506635</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaiwa K, et al. Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Cell Death Dis 8, e2934 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550882</ArticleId><ArticleId IdType="pubmed">28703795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jami MS, et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int 90, 134&#x2013;141 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675627</ArticleId><ArticleId IdType="pubmed">26232623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, et al. Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation. Exp Ther Med 18, 467&#x2013;474 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580098</ArticleId><ArticleId IdType="pubmed">31281440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, Messing A &amp; Johnson JA Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 28, 13574&#x2013;13581 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C, Dib M, Garrel C &amp; Favier A A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2, 9&#x2013;18 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) 112, 649&#x2013;660 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 66, 235&#x2013;244 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE &amp; de Jong JM Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 52, 559&#x2013;564 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7763202</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahata K, Shimazu S, Katsuki H, Yoneda F &amp; Akaike A Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm (Vienna) 113, 151&#x2013;158 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">15959853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu RM, Mohanakumar KP, Murphy DL &amp; Chiueh CC Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Ann N Y Acad Sci 738, 214&#x2013;221 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7832430</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel V, Stewart SS, Smith G &amp; Appel SH A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22, 328&#x2013;333 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3118763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange DJ, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55, 93&#x2013;96 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9443715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, et al. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve 59, 201&#x2013;207 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT02460679.
Safety and Biomarker Study of EPI-589 in Subjects With ALS (EPI-589). https://clinicaltrials.gov/ct2/show/NCT02460679 (2015).</Citation></Reference><Reference><Citation>Haidet-Phillips AM, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29, 824&#x2013;828 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 7, e39216 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15, 601&#x2013;609 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T &amp; McGeer PL Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140, 691&#x2013;707 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, et al. Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron 81, 1009&#x2013;1023 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10, 615&#x2013;622 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriz J, Nguyen MD &amp; Julien JP Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10, 268&#x2013;278 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12270689</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz B, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25, 7805&#x2013;7812 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 7, e37885 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6, 1045&#x2013;1053 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuraltus. http://www.neuraltus.com/april-26-2018
Press Release (2018).</Citation></Reference><Reference><Citation>Miller RG, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2, e100 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03049046.
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS (CC100B). https://www.neals.org/als-trials/1278 (2017).</Citation></Reference><Reference><Citation>NCT03792490.
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS (ROCK-ALS). https://clinicaltrials.gov/ct2/show/NCT03792490 (2019).</Citation></Reference><Reference><Citation>Brooks BR, et al. Adaptive Design Single Center Phosphodiesterase Type 4 ( PDE4 ) Inhibitor &#x2013; Ibudilast ( MN-166-ALS-1201 ) Phase 1b / 2a Clinical Trial Double - Blind ( DB ) with Open Label Extension (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis ( ALS ) Patients [ 1 ] Not Requiring Non-Invasive Ventilation ( no NIV ) up to 5 years ( Early Cohort &#x2013; EC ) and [ 2 ] Requiring Non-Invasive Ventilation ( NIV ) up to 10 years ( Advanced NIV Cohort &#x2013; ANC ) from Disease Onset &#x2013; Report of Clinical Trial DB, OLE and Post-Treatment Cessation Epochs &#x2013; Per-Protocol (PP) Treatment Completion Associated with Improved Survival and Post Treatment Cessation Loss of Muscle Strength (P3.127). Neurology 88(2017).</Citation></Reference><Reference><Citation>Meininger V, et al. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 66, 88&#x2013;92 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stommel EW, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler 10, 393&#x2013;404 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820489</ArticleId><ArticleId IdType="pubmed">19922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutical Ono. https://www.ono.co.jp/eng/cn/contents/sm_cn_050810.pdf
Press Release. (2005).</Citation></Reference><Reference><Citation>Khasnavis S, et al. Suppression of nuclear factor-kappaB activation and inflammation in microglia by physically modified saline. J Biol Chem 287, 29529&#x2013;29542 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436140</ArticleId><ArticleId IdType="pubmed">22753407</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379136</ArticleId><ArticleId IdType="pubmed">30458059</ArticleId></ArticleIdList></Reference><Reference><Citation>Denali. http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-positive-clinical-results-its-lead#ir-pages
Press Release. (2018).</Citation></Reference><Reference><Citation>Ito Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353, 603&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Ofengeim D &amp; Yuan J Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci U S A 116, 9714&#x2013;9722 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525537</ArticleId><ArticleId IdType="pubmed">31048504</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation 13, 177 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940876</ArticleId><ArticleId IdType="pubmed">27400786</ArticleId></ArticleIdList></Reference><Reference><Citation>Science AB. http://www.ab-science.com/file_bdd/content/1489992646_ALSFinalResultsENVF.pdf. Press Release. (2017).</Citation></Reference><Reference><Citation>Mora JS, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener, 1&#x2013;10 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>AB Science. http://www.ab-science.com/file_bdd/content/1527524735_CPALSUpdateVEngVF.pdf
Press Release. (2018).</Citation></Reference><Reference><Citation>European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004398/WC500252739.pdf
Assessment Report. (2018).</Citation></Reference><Reference><Citation>Berry JD, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve 56, 1077&#x2013;1084 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724488</ArticleId><ArticleId IdType="pubmed">28662296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandala S, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346&#x2013;349 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11923495</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrempf W &amp; Ziemssen T Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6, 469&#x2013;475 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17643935</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 10, 378&#x2013;383 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19922128</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03039673.
MIROCALS: Modifying Immune Response and OutComes in ALS (MIROCALS). https://clinicaltrials.gov/ct2/show/NCT03039673 (2017).</Citation></Reference><Reference><Citation>NCT02469896.
A Trial of Tocilizumab in ALS Subjects (TCZALS-001). https://clinicaltrials.gov/ct2/show/NCT02469896 (2015).</Citation></Reference><Reference><Citation>Fiala M, Mizwicki MT, Weitzman R, Magpantay L &amp; Nishimoto N Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis 2, 129&#x2013;139 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703125</ArticleId><ArticleId IdType="pubmed">23844337</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, et al. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study. PLoS One 10, e0139684 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596620</ArticleId><ArticleId IdType="pubmed">26444282</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell AJ, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med 18, 452&#x2013;455 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296825</ArticleId><ArticleId IdType="pubmed">22344294</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 17, 426&#x2013;435 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26982815</ArticleId></ArticleIdList></Reference><Reference><Citation>Collibee SE, et al. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett 9, 354&#x2013;358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5900333</ArticleId><ArticleId IdType="pubmed">29670700</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve 57, 729&#x2013;734 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681065</ArticleId><ArticleId IdType="pubmed">29150952</ArticleId></ArticleIdList></Reference><Reference><Citation>28th International Symposium on ALS/MND. Theme 9 Clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 18, 228&#x2013;244 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29113474</ArticleId></ArticleIdList></Reference><Reference><Citation>29th International Symposium on ALS/MND. Theme 9 Clinical trials and trial design. Amyotroph Lateral Scler Frontotemporal Degener 19, 264&#x2013;281; CLT-225 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30457008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward LJ, et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem 277, 15923&#x2013;15931 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11854284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton JB, et al. Cu(II)(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep 7, 42292 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 34, 8021&#x2013;8031 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT02870634.
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND. https://www.clinicaltrials.gov/ct2/show/NCT02870634 (2016).</Citation></Reference><Reference><Citation>Reaume AG, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13, 43&#x2013;47 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A 91, 8292&#x2013;8296 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851&#x2013;1854 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange DJ, et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann Neurol 81, 837&#x2013;848 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116, 2290&#x2013;2296 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12, 435&#x2013;442 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen. http://investors.biogen.com/news-releases/news-release-details/biogen-exercises-option-ionis-develop-and-commercialize
Press Release (2018).</Citation></Reference><Reference><Citation>Therapeutics Voyager. http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&amp;p=irol-newsArticle_pf&amp;id=2349776
Press Release. (2018).</Citation></Reference><Reference><Citation>Kulkarni A, Chen J &amp; Maday S Neuronal autophagy and intercellular regulation of homeostasis in the brain. Curr Opin Neurobiol 51, 29&#x2013;36 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29529415</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A &amp; Yue Z Autophagy and its normal and pathogenic states in the brain. Annu Rev Neurosci 37, 55&#x2013;78 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24821313</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, et al. Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol 68, 1057&#x2013;1061 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357952</ArticleId><ArticleId IdType="pubmed">21825243</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhang X &amp; Le W Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 4, 290&#x2013;293 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18196963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 70, 349&#x2013;359 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda E, Brannstrom T, Andersen PM &amp; Marklund SL Low autophagy capacity implicated in motor system vulnerability to mutant superoxide dismutase. Acta Neuropathol Commun 4, 6 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727314</ArticleId><ArticleId IdType="pubmed">26810478</ArticleId></ArticleIdList></Reference><Reference><Citation>U. KMND-LiCALS Study Group, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12, 339&#x2013;345 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 83, 557&#x2013;564 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore) 97, e11119 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M &amp; Sabatini DM mTOR signaling at a glance. J Cell Sci 122, 3589&#x2013;3594 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758797</ArticleId><ArticleId IdType="pubmed">19812304</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S &amp; Holzbaur EL Compartment-Specific Regulation of Autophagy in Primary Neurons. J Neurosci 36, 5933&#x2013;5945 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887563</ArticleId><ArticleId IdType="pubmed">27251616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov AS, et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci U S A 107, 16982&#x2013;16987 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947884</ArticleId><ArticleId IdType="pubmed">20833817</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol 10, 677&#x2013;685 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT00214110.
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]. https://clinicaltrials.gov/ct2/show/NCT00214110 (2005).</Citation></Reference><Reference><Citation>Henriques A, Pitzer C &amp; Schneider A Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci 4, 32 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902233</ArticleId><ArticleId IdType="pubmed">20592948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbauer PT &amp; Holtzman DM Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol 59, 444&#x2013;447 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16489617</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583&#x2013;586 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9710040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49, 1621&#x2013;1630 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9409357</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 39, 256&#x2013;260 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8967757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson EJ, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770&#x2013;1775 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46, 1244&#x2013;1249 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8628460</ArticleId></ArticleIdList></Reference><Reference><Citation>The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52, 1427&#x2013;1433 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10227630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauria G, et al. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry 86, 879&#x2013;886 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515982</ArticleId><ArticleId IdType="pubmed">25595151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindy M, Lupinacci P, Chau R, Shum T &amp; Ko D A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C). F1000Res 6, 230 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051227</ArticleId><ArticleId IdType="pubmed">30057745</ArticleId></ArticleIdList></Reference><Reference><Citation>Warita H, et al. Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP-100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial. J Clin Pharmacol 59, 677&#x2013;687 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30536581</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 5, 107&#x2013;117 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15204012</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT00748501.
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS). https://clinicaltrials.gov/ct2/show/NCT00748501 (2008).</Citation></Reference><Reference><Citation>Newron Pharmaceuticals. http://www.newron.com/user/download.aspx?FILE=OBJ00560.PDF&amp;TIPO=FLE&amp;NOME=sNN0029_start_ph_II_EN
Press Release. (2015).</Citation></Reference><Reference><Citation>Sufit RL, Ajroud-Driss S, Casey P &amp; Kessler JA Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 18, 269&#x2013;278 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28166654</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ &amp; De Vos KJ The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett (2017).</Citation></Reference><Reference><Citation>Crompton M The mitochondrial permeability transition pore and its role in cell death. Biochem J 341 ( Pt 2), 233&#x2013;249 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220352</ArticleId><ArticleId IdType="pubmed">10393078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 12, 1059&#x2013;1067 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 21, 529&#x2013;536 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53, 437&#x2013;445 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastula DM, Moore DH &amp; Bedlack RS Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 12, CD005225 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23235621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler 9, 266&#x2013;272 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A clinical trial of creatine in ALS. Neurology 63, 1656&#x2013;1661 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 14, 397&#x2013;405 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Savelieff MG, Sakowski SA &amp; Feldman EL Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs 28, 525&#x2013;543 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH, Glass JD &amp; Svendsen CN Stem cell transplantation for amyotrophic lateral sclerosis. Curr Opin Neurol 31, 655&#x2013;661 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30080719</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03280056.
Safety and Efficacy of Repeated Administrations of NurOwn&#xae; in ALS Patients. https://clinicaltrials.gov/ct2/show/NCT03280056 (2017).</Citation></Reference><Reference><Citation>Petrou P, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol 73, 337&#x2013;344 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulis NM, et al. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 8, 172&#x2013;176 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22158518</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman EL, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 75, 363&#x2013;373 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005820</ArticleId><ArticleId IdType="pubmed">24510776</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30, 1144&#x2013;1151 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22415942</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology 87, 392&#x2013;400 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadesse T, et al. Analysis of graft survival in a trial of stem cell transplant in ALS. Ann Clin Transl Neurol 1, 900&#x2013;908 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265061</ArticleId><ArticleId IdType="pubmed">25540804</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol 5, 730&#x2013;740 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR &amp; Silani V Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 13, 1127&#x2013;1138 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9, 4&#x2013;15 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03626012.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis. https://clinicaltrials.gov/ct2/show/NCT03626012 (2018).</Citation></Reference><Reference><Citation>Matthews RT, Yang L, Browne S, Baik M &amp; Beal MF Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95, 8892&#x2013;8897 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittrich F, Thoenen H &amp; Sendtner M Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol 35, 151&#x2013;163 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8109896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM &amp; Miller TM Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron 94, 1056&#x2013;1070 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821515</ArticleId><ArticleId IdType="pubmed">28641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 379, 22&#x2013;31 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29972757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, et al. Targeting Huntingtin Expression in Patients with Huntington&#x2019;s Disease. N Engl J Med 380, 2307&#x2013;2316 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155&#x2013;165 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7813012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartegni L &amp; Krainer AR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30, 377&#x2013;384 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey DR Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci 20, 497&#x2013;499 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28192393</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 377, 1723&#x2013;1732 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature Medicine News. Tailored treatment for ALS poised to move ahead. https://www.nature.com/articles/d41591-019-00013-w (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32467611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature Medicine News. Antisense therapies pose a regulatory conundrum. https://www.nature.com/articles/d41591-019-00014-9 (2019).</Citation></Reference><Reference><Citation>Lorenzetti D, Bohlega S &amp; Zoghbi HY The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. Neurology 49, 1009&#x2013;1013 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9339681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14, 277&#x2013;284 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 20, 1697&#x2013;1700 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 22, 167&#x2013;179 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 22, 180&#x2013;190 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y &amp; Brangwynne CP Liquid phase condensation in cell physiology and disease. Science 357(2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28935776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes E &amp; Shorter J The molecular language of membraneless organelles. J Biol Chem 294, 7115&#x2013;7127 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509512</ArticleId><ArticleId IdType="pubmed">30045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J &amp; Gitler AD Stress granules as crucibles of ALS pathogenesis. J Cell Biol 201, 361&#x2013;372 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 5, e13250 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet 19, 4160&#x2013;4175 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J &amp; Fawzi NL ALS Mutations Disrupt Phase Separation Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure 24, 1537&#x2013;1549 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK &amp; Parker R Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell 60, 208&#x2013;219 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, et al. ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron 88, 678&#x2013;690 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell 162, 1066&#x2013;1077 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, et al. Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization. Mol Cell 71, 703&#x2013;717 e709 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, et al. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain. J Biol Chem 294, 6306&#x2013;6317 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, et al. Chronic optogenetic induction of stress granules is cytotoxic and reveals the evolution of ALS-FTD pathology. Elife 8(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426440</ArticleId><ArticleId IdType="pubmed">30893049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron 102, 339&#x2013;357 e337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron 102, 321&#x2013;338 e328 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int 60, 415&#x2013;424 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22306778</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrusiak MG, et al. Inhibition of Axon Regeneration by Liquid-like TIAR-2 Granules. Neuron (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813885</ArticleId><ArticleId IdType="pubmed">31378567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo PK, et al. Axonal G3BP1 stress granule protein limits axonal mRNA translation and nerve regeneration. Nat Commun 9, 3358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105716</ArticleId><ArticleId IdType="pubmed">30135423</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MY, et al. Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. Neuron (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale A, Paldino E, Giampa C, Bernardi G &amp; Fusco FR PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington&#x2019;s Disease. PLoS One 10, e0134482 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529170</ArticleId><ArticleId IdType="pubmed">26252217</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y, et al. PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins. Cell Res 29, 233&#x2013;247 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6460439</ArticleId><ArticleId IdType="pubmed">30728452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam TI, et al. Poly(ADP-ribose) drives pathologic alpha-synuclein neurodegeneration in Parkinson&#x2019;s disease. Science 362(2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431793</ArticleId><ArticleId IdType="pubmed">30385548</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, et al. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. Acta Neuropathol Commun 6, 84 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6114235</ArticleId><ArticleId IdType="pubmed">30157956</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y &amp; Leverson JD New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Expert Rev Anticancer Ther 5, 333&#x2013;342 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15877529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YQ, et al. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. J Med Chem 59, 9575&#x2013;9598 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27416328</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSantis ME, et al. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 778&#x2013;793 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496281</ArticleId><ArticleId IdType="pubmed">23141537</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaips CL, Hochstrasser ML, Langlois CR &amp; Serio TR Spatial quality control bypasses cell-based limitations on proteostasis to promote prion curing. Elife 3(2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270096</ArticleId><ArticleId IdType="pubmed">25490068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeny EA &amp; Shorter J Mechanistic and Structural Insights into the Prion-Disaggregase Activity of Hsp104. J Mol Biol 428, 1870&#x2013;1885 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860052</ArticleId><ArticleId IdType="pubmed">26608812</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J &amp; Lindquist S Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 23, 425&#x2013;438 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1540446</ArticleId><ArticleId IdType="pubmed">16885031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J &amp; Southworth DR Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase. Cold Spring Harb Perspect Biol (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671941</ArticleId><ArticleId IdType="pubmed">30745294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME &amp; Shorter J Reversing deleterious protein aggregation with re-engineered protein disaggregases. Cell Cycle 13, 1379&#x2013;1383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050135</ArticleId><ArticleId IdType="pubmed">24694655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A, et al. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. FEMS Yeast Res 18(2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454557</ArticleId><ArticleId IdType="pubmed">29788207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, Yee K, Tariq A, Chen AI &amp; Shorter J Disparate Mutations Confer Therapeutic Gain of Hsp104 Function. ACS Chem Biol 10, 2672&#x2013;2679 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684741</ArticleId><ArticleId IdType="pubmed">26441009</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME &amp; Shorter J Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis Model Mech 7, 1175&#x2013;1184 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174528</ArticleId><ArticleId IdType="pubmed">25062688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel ME, et al. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170&#x2013;182 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3909490</ArticleId><ArticleId IdType="pubmed">24439375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A, et al. Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and alpha-Synuclein Proteotoxicity. Cell Rep 28, 2080&#x2013;2095 e2086 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750954</ArticleId><ArticleId IdType="pubmed">31433984</ArticleId></ArticleIdList></Reference><Reference><Citation>Erives AJ &amp; Fassler JS Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. PLoS One 10, e0117192 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339202</ArticleId><ArticleId IdType="pubmed">25710177</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J Designer protein disaggregases to counter neurodegenerative disease. Curr Opin Genet Dev 44, 1&#x2013;8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447488</ArticleId><ArticleId IdType="pubmed">28208059</ArticleId></ArticleIdList></Reference><Reference><Citation>March ZM, Mack KL &amp; Shorter J AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease. Biophys J 116, 1380&#x2013;1385 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486517</ArticleId><ArticleId IdType="pubmed">30952364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K, Clatterbuck-Soper SF, Jackrel ME, Shorter J &amp; Mili S FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. J Cell Biol 216, 1015&#x2013;1034 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5379945</ArticleId><ArticleId IdType="pubmed">28298410</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Fare CM &amp; Shorter J Therapeutic Dissolution of Aberrant Phases by Nuclear-Import Receptors. Trends Cell Biol 29, 308&#x2013;322 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, et al. Nuclear Import Receptor Inhibits Phase Separation of FUS through Binding to Multiple Sites. Cell 173, 693&#x2013;705 e622 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, et al. FUS Phase Separation Is Modulated by a Molecular Chaperone and Methylation of Arginine Cation-pi Interactions. Cell 173, 720&#x2013;734 e715 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, et al. Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. Cell 173, 706&#x2013;719 e713 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, et al. Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. Cell 173, 677&#x2013;692 e620 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11, 323&#x2013;330 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A &amp; Traynor BJ State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17, 17&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R &amp; Isaacs AM C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14, 544&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 110, E4968&#x2013;4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128, 485&#x2013;503 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum Mol Genet 24, 2426&#x2013;2441 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan A, et al. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Hum Mol Genet 27, 1754&#x2013;1762 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932562</ArticleId><ArticleId IdType="pubmed">29528390</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, et al. Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron 87, 1207&#x2013;1214 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol 137, 487&#x2013;500 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514073</ArticleId><ArticleId IdType="pubmed">30604225</ArticleId></ArticleIdList></Reference><Reference><Citation>White MR, et al. C9orf72 Poly(PR) Dipeptide Repeats Disturb Biomolecular Phase Separation and Disrupt Nucleolar Function. Mol Cell 74, 713&#x2013;728 e716 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525025</ArticleId><ArticleId IdType="pubmed">30981631</ArticleId></ArticleIdList></Reference><Reference><Citation>Frottin F, et al. The nucleolus functions as a phase-separated protein quality control compartment. Science 365, 342&#x2013;347 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31296649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada SB, et al. RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nat Neurosci (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713615</ArticleId><ArticleId IdType="pubmed">31358992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, et al. CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6895427</ArticleId><ArticleId IdType="pubmed">31587919</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, et al. High-throughput screening yields several small-molecule inhibitors of repeat-associated non-AUG translation. J Biol Chem (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6901296</ArticleId><ArticleId IdType="pubmed">31649034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett 583, 394&#x2013;400 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19111550</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol 130, 643&#x2013;660 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerner AC, et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science 351, 173&#x2013;176 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26634439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21, 228&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma (2019).</Citation></Reference><Reference><Citation>Archbold HC, et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep 8, 4606 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci Rep 8, 7084 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, et al. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep 8, 7083 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestrini MJ, et al. Nuclear Export Inhibition Enhances HLH-30/TFEB Activity, Autophagy, and Lifespan. Cell Rep 23, 1915&#x2013;1921 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991088</ArticleId><ArticleId IdType="pubmed">29768192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>VanMeter S, Becker P, Mackey L, Fang L &amp; Zhao E Post hoc analysis using PRO-ACT database to evaluate Repository Corticotropin Injection (H.P. Acthar&#xae; Gel) as a potential treatment for ALS (P5.327). Neurology 90, P5.327 (2018).</Citation></Reference><Reference><Citation>Mallinckrodt. http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=25976 (Press Release). (2019).</Citation></Reference><Reference><Citation>Kovalchuk MO, et al. Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Clin Pharmacol Ther (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, Askmark H &amp; Persson LI A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 108, 1&#x2013;8 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12807386</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 16, 208&#x2013;216 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT02655614. A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis. (2016).</Citation></Reference><Reference><Citation>NCT00886977.
Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS). https://clinicaltrials.gov/ct2/show/NCT00886977 (2009).</Citation></Reference><Reference><Citation>Kaji R, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten SA, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2(2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5752378</ArticleId><ArticleId IdType="pubmed">29202456</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69, 776&#x2013;784 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17709710</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, et al. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6067092</ArticleId><ArticleId IdType="pubmed">29287521</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 23, 45&#x2013;52 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10, 99&#x2013;106 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology 90, e565&#x2013;e574 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Elysium. https://www.elysiumhealth.com/en-us/knowledge/press/elysium-health-granted-orphan-drug-designation-for-eh301-to-treat-als
Press Release. (2018).</Citation></Reference><Reference><Citation>NCT03114215. Effect of MD1003 in Amyotrophic Lateral Sclerosis (MD1003-ALS). (2017).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>